Veracyte Inc (VCYT)

Currency in USD
27.37
-0.31(-1.12%)
Closed·
After Hours
27.370.00(0.00%)
·
VCYT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VCYT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
27.3528.69
52 wk Range
22.6147.32
Key Statistics
Prev. Close
27.68
Open
27.77
Day's Range
27.35-28.69
52 wk Range
22.61-47.32
Volume
1.54M
Average Volume (3m)
1.4M
1-Year Change
-6.49%
Book Value / Share
15.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VCYT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
39.63
Upside
+44.78%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Veracyte Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Veracyte Inc Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.44 beat $0.11 forecast; revenue of $130.2M exceeded expectations. Stock fell 4.16% after hours despite results.
  • Full-year revenue guidance raised to $496-$500M. Testing volume up 15%, with Decipher prostate test showing 28% growth.
  • Company ended Q2 with $320.7M cash. Plans to launch new tests for metastatic population and muscle-invasive bladder cancer.
  • CEO emphasized patient-centric innovation; CFO confident in double-digit revenue growth. Analysts focused on metastatic Decipher test.
  • Veracyte faces challenges in market differentiation, competition, economic uncertainty, and potential regulatory changes.
Last Updated: 07/08/2025, 08:50
Read Full Transcript

Compare VCYT to Peers and Sector

Metrics to compare
VCYT
Peers
Sector
Relationship
P/E Ratio
81.8x−3.7x−0.5x
PEG Ratio
0.56−0.190.00
Price/Book
1.8x3.0x2.6x
Price / LTM Sales
4.5x7.3x3.3x
Upside (Analyst Target)
51.6%318.4%43.4%
Fair Value Upside
Unlock−7.5%7.1%Unlock

Analyst Ratings

8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 39.63
(+44.78% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
0.44 / 0.11
Revenue / Forecast
130.16M / 121.10M
EPS Revisions
Last 90 days

VCYT Income Statement

People Also Watch

15.46
PD
-0.83%
23.81
IRDM
+0.29%
60.87
TEM
+3.63%
51.43
BMNR
+24.59%
17.62
BEAM
-1.34%

FAQ

What Stock Exchange Does Veracyte Inc Trade On?

Veracyte Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Veracyte Inc?

The stock symbol for Veracyte Inc is "VCYT."

What Is the Veracyte Inc Market Cap?

As of today, Veracyte Inc market cap is 2.15B.

What Is Veracyte Inc's Earnings Per Share (TTM)?

The Veracyte Inc EPS (TTM) is 0.34.

When Is the Next Veracyte Inc Earnings Date?

Veracyte Inc will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is VCYT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Veracyte Inc Stock Split?

Veracyte Inc has split 0 times.

How Many Employees Does Veracyte Inc Have?

Veracyte Inc has 824 employees.

What is the current trading status of Veracyte Inc (VCYT)?

As of 10 Aug 2025, Veracyte Inc (VCYT) is trading at a price of 27.37, with a previous close of 27.68. The stock has fluctuated within a day range of 27.35 to 28.69, while its 52-week range spans from 22.61 to 47.32.

What Is Veracyte Inc (VCYT) Price Target According to Analysts?

The average 12-month price target for Veracyte Inc is USD39.625, with a high estimate of USD45 and a low estimate of USD28. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +44.78% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.